158 related articles for article (PubMed ID: 29534639)
1. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Nagel M; Schulz J; Maderer A; Goepfert K; Gehrke N; Thomaidis T; Thuss-Patience PC; Al-Batran SE; Hegewisch-Becker S; Grimminger P; Galle PR; Möhler M; Schattenberg JM
Tumour Biol; 2018 Mar; 40(3):1010428318764007. PubMed ID: 29534639
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
3. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
[TBL] [Abstract][Full Text] [Related]
4. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Chu T; Jiang L; Ying W; Han B
Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.
Turk HM; Aliyev A; Celik RS; Seker M; Coban E; Demir T; Baydas T; Kocyigit A
Curr Probl Cancer; 2020 Feb; 44(1):100497. PubMed ID: 31371034
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Moehler M; Gepfner-Tuma I; Maderer A; Thuss-Patience PC; Ruessel J; Hegewisch-Becker S; Wilke H; Al-Batran SE; Rafiyan MR; Weißinger F; Schmoll HJ; Kullmann F; von Weikersthal LF; Siveke JT; Weusmann J; Kanzler S; Schimanski CC; Otte M; Schollenberger L; Koenig J; Galle PR
BMC Cancer; 2016 Aug; 16(1):699. PubMed ID: 27582078
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
8. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.
Yildiz I; Tas F; Kilic L; Sen F; Saip P; Eralp Y; Keskin S; Karabulut S; Ciftci R; Serilmez M; Yasasever V; Aydiner A
Cancer Chemother Pharmacol; 2013 Aug; 72(2):437-44. PubMed ID: 23801282
[TBL] [Abstract][Full Text] [Related]
9. Serum M65 as a biomarker for metastatic renal cell carcinoma.
Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
[TBL] [Abstract][Full Text] [Related]
10. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
Ustaalioglu BB; Bilici A; Ercan S; Seker M; Orcun A; Gumus M
Med Oncol; 2013 Jun; 30(2):551. PubMed ID: 23536001
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin 18 as a biomarker for gastric cancer.
Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.
Tas F; Karabulut S; Bilgin E; Sen F; Yildiz I; Tastekin D; Ciftci R; Duranyildiz D
Tumour Biol; 2013 Dec; 34(6):3529-36. PubMed ID: 23784459
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma.
Sen F; Yildiz I; Odabas H; Tambas M; Kilic L; Karadeniz A; Altun M; Ekenel M; Serilmez M; Duranyildiz D; Bavbek S; Basaran M
Tumour Biol; 2015 Feb; 36(2):1039-44. PubMed ID: 25326440
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
Tas F; Karabulut S; Yildiz I; Duranyildiz D
Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
17. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Kwon HJ; Park MI; Park SJ; Moon W; Kim SE; Lee HW; Choi YJ; Kim JH
Korean J Gastroenterol; 2015 Jul; 66(1):10-6. PubMed ID: 26194124
[TBL] [Abstract][Full Text] [Related]
20. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
